
A small, randomized clinical trial from Germany suggests that two weeks of high-dose oral prednisone produces a clinically relevant response in patients with active ankylyosing spondylitis (AS) refractory to NSAIDs.

A small, randomized clinical trial from Germany suggests that two weeks of high-dose oral prednisone produces a clinically relevant response in patients with active ankylyosing spondylitis (AS) refractory to NSAIDs.

A 24-week randomized trial showed that quick response to the biologic adalimumab strongly predicted remission lasting for five years.

The spectrum of spondyloarthritis disorders-typically including ankylosing spondylitis, arthritis associated with inflammatory bowel disease, reactive arthritis, psoriatic arthritis, and undifferentiated SpA-are related clinically and genetically but are distinct entities.

The signs and symptoms can be controlled with early diagnosis and treatment.